|
US2292551A
(en)
*
|
1940-01-26 |
1942-08-11 |
Du Pont |
Naphthostyril-5-carboxylic acid
|
|
IT1123076B
(it)
*
|
1976-11-17 |
1986-04-30 |
Acna |
Procedimento di preparazione diretta di 6-amino-benz-(cd)-indol-2-(1h)-oni-n-mono oppure n,n-disostituiti
|
|
DE2921690A1
(de)
*
|
1979-05-29 |
1980-12-11 |
Basf Ag |
Naphtholactamderivate
|
|
IL99500A0
(en)
*
|
1990-09-17 |
1992-08-18 |
Agouron Pharma |
Naphthalene compounds,processes for the preparation thereof and pharmaceutical compositions containing the same
|
|
DE69123241T2
(de)
|
1990-12-14 |
1997-04-17 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
|
JP3286056B2
(ja)
*
|
1993-01-18 |
2002-05-27 |
武田薬品工業株式会社 |
三環式縮合複素環誘導体、その製造法および用途
|
|
US5565215A
(en)
|
1993-07-23 |
1996-10-15 |
Massachusettes Institute Of Technology |
Biodegradable injectable particles for imaging
|
|
GB9322014D0
(en)
|
1993-10-26 |
1993-12-15 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
SE9401108D0
(sv)
|
1994-03-31 |
1994-03-31 |
Leiras Oy |
Ophthalmic composition I
|
|
SE9401109D0
(sv)
|
1994-03-31 |
1994-03-31 |
Leiras Oy |
Opthalmic composition II
|
|
GB9412273D0
(en)
|
1994-06-18 |
1994-08-10 |
Univ Nottingham |
Administration means
|
|
US6007845A
(en)
|
1994-07-22 |
1999-12-28 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
|
GB9501841D0
(en)
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
US6413539B1
(en)
|
1996-10-31 |
2002-07-02 |
Poly-Med, Inc. |
Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
|
|
GB9515182D0
(en)
|
1995-07-24 |
1995-09-20 |
Co Ordinated Drug Dev |
Improvements in and relating to powders for use in dry powder inhalers
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
EP1064277B1
(en)
|
1998-03-16 |
2005-06-15 |
Celgene Corporation |
2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
GB9827145D0
(en)
|
1998-12-09 |
1999-02-03 |
Co Ordinated Drug Dev |
Improvements in or relating to powders
|
|
US6287588B1
(en)
|
1999-04-29 |
2001-09-11 |
Macromed, Inc. |
Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
|
|
EP1279406A4
(en)
|
2000-04-03 |
2007-10-24 |
Santen Pharmaceutical Co Ltd |
TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
|
|
GB0009468D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formulations for use in inhaler devices
|
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
|
PT1296651E
(pt)
|
2000-06-27 |
2008-02-12 |
Vectura Ltd |
Método para fazer partículas para serem usadas numa composição farmacêutica
|
|
GB2364919A
(en)
|
2000-07-21 |
2002-02-13 |
Cambridge Consultants |
Inhalers
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
ES2382636T3
(es)
|
2000-10-31 |
2012-06-12 |
Surmodics Pharmaceuticals, Inc. |
Método para producir composiciones para la administración mejorada de moléculas bioactivas
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
EP2168571B1
(en)
|
2000-11-30 |
2018-08-22 |
Vectura Limited |
Particles for use in a Pharmaceutical Composition
|
|
US6504034B2
(en)
*
|
2001-01-23 |
2003-01-07 |
Hoffmann-La Roche Inc. |
Naphthostyrils
|
|
GB0122318D0
(en)
|
2001-09-14 |
2001-11-07 |
Novartis Ag |
Organic compounds
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7230012B2
(en)
|
2002-11-14 |
2007-06-12 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
NZ545484A
(en)
|
2003-09-15 |
2009-09-25 |
Vectura Ltd |
Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
|
|
CA2539324A1
(en)
|
2003-09-18 |
2005-03-31 |
Macusight, Inc. |
Transscleral delivery
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
GB0407627D0
(en)
|
2004-04-02 |
2004-05-05 |
Vectura Ltd |
Corkscrew pump
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
WO2006026746A2
(en)
|
2004-08-31 |
2006-03-09 |
The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to separate and expand antigen-specific t cells
|
|
JP4974903B2
(ja)
|
2005-02-09 |
2012-07-11 |
参天製薬株式会社 |
疾患または状態を処置するための液体処方物
|
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
|
US20070071756A1
(en)
|
2005-09-26 |
2007-03-29 |
Peyman Gholam A |
Delivery of an agent to ameliorate inflammation
|
|
US8663674B2
(en)
|
2006-01-13 |
2014-03-04 |
Surmodics, Inc. |
Microparticle containing matrices for drug delivery
|
|
PL2001466T3
(pl)
|
2006-03-23 |
2016-06-30 |
Santen Pharmaceutical Co Ltd |
Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
|
|
US20080166411A1
(en)
|
2006-04-10 |
2008-07-10 |
Pfizer Inc |
Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
|
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
MX2009001989A
(es)
|
2006-08-30 |
2009-03-09 |
Celgene Corp |
Compuestos de isoindolina 5-substituidos.
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
PL2076260T3
(pl)
|
2006-09-15 |
2011-08-31 |
Celgene Corp |
Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
|
|
DK2428513T3
(en)
|
2006-09-26 |
2017-08-21 |
Celgene Corp |
5-substituted quinazolinone derivatives as anti-cancer agents
|
|
KR101791757B1
(ko)
|
2007-03-20 |
2017-10-30 |
셀진 코포레이션 |
4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
|
|
AU2008305581C1
(en)
|
2007-09-26 |
2014-12-11 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
|
|
WO2009145842A2
(en)
|
2008-04-04 |
2009-12-03 |
Forsight Labs, Llc |
Therapeutic device for pain management and vision
|
|
US20090298882A1
(en)
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
PT2315773T
(pt)
|
2008-07-25 |
2016-11-23 |
Glaxosmithkline Biologicals Sa |
Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente
|
|
PE20110547A1
(es)
|
2008-10-29 |
2011-08-04 |
Celgene Corp |
Compuestos de isoindolina con actividad anticancerigena
|
|
US8399006B2
(en)
|
2009-01-29 |
2013-03-19 |
Forsight Vision4, Inc. |
Posterior segment drug delivery
|
|
US8623395B2
(en)
|
2010-01-29 |
2014-01-07 |
Forsight Vision4, Inc. |
Implantable therapeutic device
|
|
US20120052041A1
(en)
|
2009-02-04 |
2012-03-01 |
The Brigham And Women's Hospital, Inc. |
Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
|
|
EP2395930A4
(en)
|
2009-02-10 |
2013-04-10 |
Psivida Inc |
EYE TROWART ASSEMBLY
|
|
US10952965B2
(en)
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
|
AU2010249615B2
(en)
|
2009-05-19 |
2013-07-18 |
Celgene Corporation |
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
|
|
EP2437684B1
(en)
|
2009-06-03 |
2022-06-15 |
ForSight Vision5, Inc. |
Anterior segment drug delivery
|
|
EP3101122B1
(en)
|
2009-08-24 |
2023-06-14 |
Baylor College of Medicine |
Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
|
|
NZ620174A
(en)
|
2009-09-16 |
2016-08-26 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
|
WO2011050327A1
(en)
|
2009-10-23 |
2011-04-28 |
Forsight Labs Llc |
Corneal denervation for treatment of ocular pain
|
|
US9498385B2
(en)
|
2009-10-23 |
2016-11-22 |
Nexisvision, Inc. |
Conformable therapeutic shield for vision and pain
|
|
US10166142B2
(en)
|
2010-01-29 |
2019-01-01 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
|
HUE033581T2
(hu)
|
2010-06-10 |
2017-12-28 |
Seragon Pharmaceuticals Inc |
Ösztrogén receptor modulátorok és alkalmazásaik
|
|
EP3861969A1
(en)
|
2010-08-05 |
2021-08-11 |
ForSight Vision4, Inc. |
Injector apparatus for drug delivery
|
|
US20130274692A1
(en)
|
2010-08-05 |
2013-10-17 |
Yair Alster |
Subconjuctival implant for posterior segment drug delivery
|
|
JP6111194B2
(ja)
|
2010-08-05 |
2017-04-05 |
フォーサイト・ビジョン フォー・インコーポレーテッド |
組み合わせ薬物送達方法および装置
|
|
SI2600812T1
(sl)
|
2010-08-05 |
2021-12-31 |
ForSight Vision4, Inc., |
Naprava za zdravljenje očesa
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
WO2012065006A2
(en)
|
2010-11-11 |
2012-05-18 |
Forsight Vision4, Inc. |
Methods and apparatus to determine porous structures for drug delivery
|
|
TW201304822A
(zh)
|
2010-11-15 |
2013-02-01 |
Vectura Ltd |
組成物及用途
|
|
WO2012068549A2
(en)
|
2010-11-19 |
2012-05-24 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012175481A1
(en)
|
2011-06-20 |
2012-12-27 |
Institut Curie |
Compositions and methods for treating leukemia
|
|
EP2755615B1
(en)
|
2011-09-14 |
2022-04-06 |
Forsight Vision5, Inc. |
Ocular insert apparatus
|
|
RS61758B1
(sr)
|
2011-09-16 |
2021-05-31 |
Forsight Vision4 Inc |
Aparati za razmenu tečnosti
|
|
US9708384B2
(en)
|
2011-09-22 |
2017-07-18 |
The Trustees Of The University Of Pennsylvania |
Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
CN104769104A
(zh)
|
2011-12-12 |
2015-07-08 |
细胞药物有限公司 |
扩大t细胞的方法
|
|
PT2797652T
(pt)
|
2011-12-27 |
2019-02-19 |
Vectura Gmbh |
Dispositivo para inalação com sistema de feedback
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
US10010448B2
(en)
|
2012-02-03 |
2018-07-03 |
Forsight Vision4, Inc. |
Insertion and removal methods and apparatus for therapeutic devices
|
|
PT2812431T
(pt)
|
2012-02-09 |
2019-10-18 |
Baylor College Medicine |
Pepmixes para gerar ctls multivirais com larga especifidade
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
CN104271187B
(zh)
|
2012-03-09 |
2018-01-12 |
维克多瑞有限责任公司 |
吸入装置的混合通道与吸入装置
|
|
US20140107025A1
(en)
|
2012-04-16 |
2014-04-17 |
Jade Therapeutics, Llc |
Ocular drug delivery system
|
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
|
|
JP5998717B2
(ja)
|
2012-07-31 |
2016-09-28 |
ブラザー工業株式会社 |
液体吐出装置
|
|
BR112015005878A2
(pt)
|
2012-09-17 |
2017-07-04 |
Bind Therapeutics Inc |
nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
|
|
JP2015532928A
(ja)
|
2012-09-20 |
2015-11-16 |
アキナ， インク．Ａｋｉｎａ， Ｉｎｃ． |
充填材料を含有する生体分解可能なマイクロカプセル
|
|
DK2911623T3
(da)
|
2012-10-26 |
2019-10-28 |
Forsight Vision5 Inc |
Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
|
|
PL2724741T3
(pl)
|
2012-10-26 |
2017-11-30 |
Vectura Gmbh |
Urządzenie inhalacyjne do stosowania w terapii aerozolowej
|
|
EP2914296B2
(en)
|
2012-11-01 |
2021-09-29 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
CA2905496A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
ES2972168T3
(es)
|
2013-03-28 |
2024-06-11 |
Forsight Vision4 Inc |
Implante oftálmico para administración de sustancias terapéuticas
|
|
CA2927321A1
(en)
|
2013-10-15 |
2015-04-23 |
Forsight Vision5, Inc. |
Formulations and methods for increasing or reducing mucus
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
WO2015085234A1
(en)
|
2013-12-06 |
2015-06-11 |
Forsight Vision4, Inc. |
Implantable therapeutic devices
|
|
IL278381B2
(en)
|
2013-12-06 |
2024-08-01 |
Celgene Corp |
Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer
|
|
MX374759B
(es)
|
2013-12-13 |
2025-03-06 |
Hoffmann La Roche |
Inhibidores de tirosina cinasa de bruton.
|
|
AU2015247817C1
(en)
|
2014-04-14 |
2022-02-10 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
AU2015357526B2
(en)
|
2014-12-05 |
2022-03-17 |
Eureka Therapeutics, Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
CN105985282B
(zh)
*
|
2015-01-28 |
2020-12-08 |
中国科学院广州生物医药与健康研究院 |
一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物及其应用
|
|
US10730870B2
(en)
|
2015-03-18 |
2020-08-04 |
Arvinas Operations, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
IL294055A
(en)
|
2015-03-20 |
2022-08-01 |
Childrens Nat Medical Ct |
Generating virus or other antigen-specific t cells from a naive t cell population
|
|
IL295224B2
(en)
|
2015-05-28 |
2025-07-01 |
Kite Pharma Inc |
Methods of conditioning patients for t cell therapy
|
|
HUE054149T2
(hu)
|
2015-06-04 |
2021-08-30 |
Arvinas Operations Inc |
Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
CN112187645B
(zh)
|
2015-06-30 |
2021-12-03 |
华为技术有限公司 |
一种路由的方法、相关设备及系统
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017011371A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
KR101818756B1
(ko)
|
2015-12-30 |
2018-02-21 |
유한회사 한국 타코닉 |
방수방식 조성물 및 이를 이용한 방수방식 필름
|
|
US10599788B2
(en)
|
2015-12-30 |
2020-03-24 |
International Business Machines Corporation |
Predicting target characteristic data
|
|
US20190016703A1
(en)
|
2015-12-30 |
2019-01-17 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
|
US20200216454A1
(en)
|
2015-12-30 |
2020-07-09 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for her3 degradation and methods of use
|
|
EP3404024B1
(en)
|
2016-01-14 |
2020-11-18 |
Kangpu Biopharmaceuticals, Ltd. |
Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
EP3445357B1
(en)
|
2016-04-22 |
2021-05-26 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of egfr and methods of use
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
WO2017197056A1
(en)
*
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
NZ749136A
(en)
|
2016-05-25 |
2023-11-24 |
Council Queensland Inst Medical Res |
Methods of immunotherapy
|
|
KR20190037243A
(ko)
|
2016-06-28 |
2019-04-05 |
지니우스 바이오테크놀로지 인코포레이티드 |
면역치료를 위한 티 세포 조성물
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
IL290809B2
(en)
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
US10933059B2
(en)
|
2016-12-16 |
2021-03-02 |
Kangpu Biopharmaceuticals. Ltd. |
Combination, application thereof and treatment method
|
|
CA3043938A1
(en)
|
2016-12-21 |
2018-06-28 |
Biotheryx, Inc. |
Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
MX2019007646A
(es)
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
AU2018211975B2
(en)
|
2017-01-26 |
2022-05-26 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
AU2018219292B2
(en)
|
2017-02-08 |
2024-09-26 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
EP3580212A4
(en)
|
2017-02-08 |
2021-03-17 |
Dana Farber Cancer Institute, Inc. |
REGULATION OF CHEMERIC ANTIGEN RECEPTORS
|
|
AU2017202864B2
(en)
|
2017-02-13 |
2020-04-23 |
Kangpu Biopharmaceuticals, Ltd. |
Combination treating prostate cancer, pharmaceutical composition and treatment method
|
|
KR102318401B1
(ko)
|
2017-02-28 |
2021-10-29 |
강푸 바이오파마슈티칼즈 리미티드 |
신규한 이소인돌린 유도체, 이의 약학 조성물 및 용도
|
|
WO2018220149A1
(en)
|
2017-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Compounds
|
|
EP3634489A4
(en)
|
2017-06-09 |
2021-03-10 |
Dana Farber Cancer Institute, Inc. |
IMPROVED METHODS FOR GENERATING SMALL MOLECULAR DEGRADERS AND DIMERIZERS
|
|
WO2018226542A1
(en)
|
2017-06-09 |
2018-12-13 |
Arvinas, Inc. |
Modulators of proteolysis and associated methods of use
|
|
EP4717317A2
(en)
|
2017-06-20 |
2026-04-01 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
TWI791552B
(zh)
|
2017-07-10 |
2023-02-11 |
美商西建公司 |
抗增生化合物及其使用方法
|
|
EP3652329B1
(en)
|
2017-07-12 |
2023-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compounds for tau protein degradation
|
|
RU2020108515A
(ru)
|
2017-07-28 |
2021-08-27 |
Эрвинэс Оперейшнс, Инк. |
Соединения и способы целевого расщепления андрогенного рецептора
|
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
WO2019079701A1
(en)
|
2017-10-20 |
2019-04-25 |
Dana-Farber Cancer Institute, Inc. |
HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
|
|
WO2019094718A1
(en)
|
2017-11-09 |
2019-05-16 |
Dana-Farber Cancer Institute, Inc. |
Methods to prevent teratogenicity of imid like molecules and imid based degraders/protacs
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
US20200354413A1
(en)
|
2017-12-15 |
2020-11-12 |
Dana-Farber Cancer Institute, Inc. |
Stabilized peptide-mediated targeted protein degradation
|
|
WO2019121562A1
(en)
|
2017-12-18 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
|
TW201945357A
(zh)
|
2018-02-05 |
2019-12-01 |
瑞士商赫孚孟拉羅股份公司 |
化合物
|
|
US11802132B2
(en)
|
2018-02-23 |
2023-10-31 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
|
JP2021519337A
(ja)
*
|
2018-03-26 |
2021-08-10 |
シー４ セラピューティクス， インコーポレイテッド |
Ｉｋａｒｏｓの分解のためのセレブロン結合剤
|
|
US20190300521A1
(en)
|
2018-04-01 |
2019-10-03 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
KR20210006356A
(ko)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
|
CA3095912A1
(en)
|
2018-04-13 |
2019-10-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN119751456A
(zh)
|
2018-04-16 |
2025-04-04 |
C4医药公司 |
螺环化合物
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
AU2019284608A1
(en)
|
2018-06-13 |
2020-12-17 |
Biotheryx, Inc. |
Aminoamide compounds
|
|
CA3102212A1
(en)
|
2018-06-29 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Immunomodulatory compounds
|
|
US12060366B2
(en)
|
2018-06-29 |
2024-08-13 |
Dana-Farber Cancer Institute, Inc. |
Bispecific degraders
|
|
EP3813834B1
(en)
|
2018-06-29 |
2025-03-26 |
Dana-Farber Cancer Institute, Inc. |
New crbn modulators
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US20220356185A1
(en)
|
2018-07-06 |
2022-11-10 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
DK3820573T3
(da)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
|
|
CA3102996A1
(en)
|
2018-07-20 |
2020-01-23 |
Dana-Farber Cancer Institute, Inc. |
Degraders that target proteins via keap1
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
EP3841100A1
(en)
|
2018-08-20 |
2021-06-30 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
KR102642203B1
(ko)
|
2018-09-07 |
2024-03-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
|
|
AU2019348011A1
(en)
|
2018-09-27 |
2021-02-11 |
Dana-Farber Cancer Institute, Inc. |
Degradation of FAK or FAK and ALK by conjugation of FAK and ALK inhibitors with E3 ligase ligands and methods of use
|
|
US12318452B2
(en)
|
2018-09-27 |
2025-06-03 |
Dana-Farber Cancer Institute, Inc. |
Degraders of WEE1 kinase
|
|
WO2020069125A1
(en)
|
2018-09-28 |
2020-04-02 |
Dana-Farber Cancer Institute, Inc. |
Degraders of hepatitis c virus ns3/4a protein
|
|
CA3151824A1
(en)
|
2019-08-27 |
2021-03-04 |
The Regents Of The University Of Michigan |
Cereblon e3 ligase inhibitors
|
|
US20240383886A1
(en)
|
2019-12-20 |
2024-11-21 |
Calico Life Sciences Llc |
Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof
|
|
MX2023001545A
(es)
*
|
2020-08-07 |
2023-05-03 |
C4 Therapeutics Inc |
Terapias ventajosas para trastornos mediados por ikaros o aiolos.
|
|
KR20240052805A
(ko)
*
|
2021-08-27 |
2024-04-23 |
항저우 글루바이오 파마수티컬 코., 엘티디. |
이소인돌리논 화합물 및 이의 용도
|
|
MX2024009897A
(es)
*
|
2022-02-09 |
2024-08-20 |
C4 Therapeutics Inc |
Formas morficas de cft7455 y sus metodos de fabricacion.
|